Observation is effective in the management of haemangioma of infancy.

Article

Using a combination of observation and amblyopia therapy is successful in mild cases of periocular haemangioma of infancy (HOI).

An investigation published in the Journal of Paediatric Ophthalmology and Strabismus has demonstrated that using a combination of observation and amblyopia therapy is successful in mild cases of periocular haemangioma of infancy (HOI).

Dr Assad Jalil et al., Manchester Royal Eye Hospital, Manchester, UK, conducted a retrospective study on 41 children. The children were divided into groups according to treatment methods. This included observation, intralesional steroid injections (ILSI), and oral steroids.

Of the children included in the research, 24 had amblyopia at presentation, 18 children were in the observation group, 17 were administered ILSI and 6 children were given oral steroids.

Success was measured when HOI regression was completed before the child was 5 years of age (cosmetic group), astigmatism was reduced by 1 dioptre cylinder (DC) (astigmatism group) or if there was no evidence of amblyopia at the last follow-up (visual axis obscuration group).

The cosmetic group demonstrated a high success rate, with all but 2 patients treated. The visual axis obscuration group saw 6 of 7 patients treated.

Mean astigmatic correction of the patients was 1.65 ± 1.34 DC pre-treatment and 0.91 ± 1.17 DC post-treatment. This proved to be statistically significant and proved that, as well as observation, ILSI and oral steroids can be effective for treating lesions. However, their role has not been completely determined with regards to spontaneously resolving lesions.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.